Home›Abacavir Sulfate Dolutegravir Sodium Lamivudine›Abacavir Sulfate Dolutegravir Sodium Lamivudine + Abacavir

Does Abacavir Sulfate Dolutegravir Sodium Lamivudine Interact with Abacavir?

CDI records a unknown classification for Abacavir Sulfate Dolutegravir Sodium Lamivudine and Abacavir. The stored summary is: 7.3 Established and Other Potentially Significant Drug Interactions There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets. Methadone Abacavir: In a trial of 11 HIV-1–infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology ( 12.3 )] . Riociguat Abacavir: Coadministration with TRIUMEQ resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see Clinical Pharmacology ( 12.3 )] . Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification
Unknown
Abacavir Sulfate Dolutegravir Sodium Lamivudine Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Abacavir Sulfate Dolutegravir Sodium Lamivudine and your doctor is considering prescribing Abacavir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Abacavir Sulfate Dolutegravir Sodium Lamivudine(Triumeq)+💊 Abacavir(Triumeq)

Severity & Interaction Details

ℹ️
unknown
Stored CDI classification: unknown
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Drug B class
—
Source
FDA drug label - abacavir sulfate, dolutegravir sodium, lamivudine

What this means in plain English

7.3 Established and Other Potentially Significant Drug Interactions There were no drug-drug interaction trials conducted with the abacavir, dolutegravir, and lamivudine fixed-dose combination tablets. Methadone Abacavir: In a trial of 11 HIV-1–infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased [see Clinical Pharmacology ( 12.3 )] . Riociguat Abacavir: Coadministration with TRIUMEQ resulted in increased riociguat exposure, which may increase the risk of riociguat adverse reactions [see Clinical Pharmacology ( 12.3 )] .

About Abacavir Sulfate Dolutegravir Sodium Lamivudine and Abacavir

Abacavir Sulfate Dolutegravir Sodium Lamivudine is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. You may recognize them by the brand names Triumeq and Triumeq. Both Abacavir Sulfate Dolutegravir Sodium Lamivudine and Abacavir carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - abacavir sulfate, dolutegravir sodium, lamivudine

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Abacavir Sulfate Dolutegravir Sodium Lamivudine and Abacavir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations